N,N-二甲基-3-氨基-4-甲基苄胺 | 107600-25-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N,N-二甲基-3-氨基-4-甲基苄胺
• 英文名称: N,N-dimethyl-3-amino-4-methylbenzylamine
• 英文别名: 5-((dimethylamino)methyl)-2-methylaniline；(3-amino-4-methylbenzyl)dimethylamine；5-[(Dimethylamino)methyl]-2-methylaniline
• CAS: 107600-25-9
• 化学式: C₁₀H₁₆N₂
• mdl: MFCD10021452
• 分子量: 164.25
• InChiKey: LUMHJHNXEBFVTB-UHFFFAOYSA-N

物化性质

• 熔点：
  73-76 °C
• 沸点：
  252.4±25.0 °C(Predicted)
• 密度：
  0.998±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  氰化亚铜 、 N,N-二甲基-3-氨基-4-甲基苄胺 在 盐酸 、 sodium nitrite 作用下， 生成 N,N-dimethyl-3-cyano-4-methylbenzylamine
  参考文献：
  名称：

  Rearrangement of (substituted benzyl)trimethylammonium ylides in a nonbasic medium: the improved Sommelet-Hauser rearrangement

  摘要：

  DOI：

  10.1021/jo00385a035
• 作为产物：
  描述：

  N,N-二甲基-3-氨基-4-甲基苯甲酰胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以72%的产率得到N,N-二甲基-3-氨基-4-甲基苄胺
  参考文献：
  名称：

  Rearrangement of (substituted benzyl)trimethylammonium ylides in a nonbasic medium: the improved Sommelet-Hauser rearrangement

  摘要：

  DOI：

  10.1021/jo00385a035

文献信息

• [EN] COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS<br/>[FR] COMPOSÉS UTILES DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À RAS MUTANT
  申请人：UNIV OXFORD INNOVATION LTD

  公开号：WO2019234405A1

  公开（公告）日：2019-12-12

  The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.

  本发明涉及式I所定义的化合物，以及它们的盐和溶剂化物。（I）本发明还涉及包含式（I）化合物的药物组合物，以及式（I）化合物用于治疗增殖性疾病，如癌症，以及其它涉及抑制RAS效应蛋白-蛋白相互作用的疾病或状况。
• [EN] AMINE COMPOUNDS<br/>[FR] DERIVES D'INDOLE SERVANT D'ANTAGONISTE DE SOMATOSTATINE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2004046107A1

  公开（公告）日：2004-06-03

  The present invention provide a compound of the formula (I) wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

  本发明提供了一种公式(I)的化合物，其中环A代表一个具有可选取代基的芳香环；B、Y和Ya相同或不同，分别代表一个键等；R1和R2相同或不同，每个代表一个氢原子等；R3代表一个氢原子等；R4和R5相同或不同，每个代表一个氢等；R6代表一个可选有取代基的吲哚基团；Z和Za相同或不同，每个代表一个氢原子等；或其盐或前药，具有生长抑素受体结合抑制活性，并且用于预防或治疗与生长抑素相关的疾病。
• Indole derivatives as somatostatin agonists or antagonists
  申请人：Abe Hidenori

  公开号：US20060223826A1

  公开（公告）日：2006-10-05

  The present invention provide a compound of the formula (I) wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R 1 and R 2 are the same or different and each represents a hydrogen atom, etc.; R 3 represents a hydrogen atom, etc.; R 4 and R 5 are the same or different and each represents a hydrogen, etc.; R 6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

  本发明提供了一种化合物(I)的公式，其中环A代表一种芳香环，可选地具有取代基; B、Y和Ya相同或不同，每个代表一种键等; R1和R2相同或不同，每个代表一个氢原子等; R3代表一个氢原子等; R4和R5相同或不同，每个代表一个氢等; R6代表一种吲哚基，可选地具有取代基; Z和Za相同或不同，每个代表一个氢原子等; 或其盐或前药，具有生长抑素受体结合抑制活性，并用于预防和/或治疗与生长抑素相关的疾病。
• INHIBITORS OF HEDGEHOG PATHWAY
  申请人：Bahceci Suleyman

  公开号：US20090105211A1

  公开（公告）日：2009-04-23

  The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

  本发明涉及公式I的化合物或其单一异构体；其中化合物可以选择作为药物可接受的盐、水合物、溶剂合物或其组合物，此外还涉及制备公式I的化合物的方法，以及使用公式I的化合物治疗癌症的方法。
• INHIBITORS OF THE HEDGEHOG PATHWAY
  申请人：Bahceci Suleyman

  公开号：US20120245139A1

  公开（公告）日：2012-09-27

  The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

  本发明涉及公式I的化合物或其单一异构体；其中所述化合物可选为药学上可接受的盐，水合物，溶剂合物或其组合物，以及制备公式I化合物的方法，以及使用公式I化合物治疗癌症的方法。